A Study to Evaluate AMG 133 Administered Subcutaneously in Participants With Overweight or Obesity

PHASE1CompletedINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

August 20, 2024

Primary Completion Date

December 27, 2024

Study Completion Date

December 27, 2024

Conditions

OverweightObesity

Interventions

DRUG

AMG 133

AMG 133 will be administered SC. Dose levels range from A to D lowest to highest.

Trial Locations (3)

Fortrea Clinical Research Unit - Dallas, Dallas

CenExel Collaborative Neuroscience Research, LLC Los Alamitos, Los Alamitos

CenExel, Anaheim